Morphologic and functional changes in the unilateral 6-hydroxydopamine lesion rat model for Parkinson’s disease discerned with μSPECT and quantitative MRI

ObjectIn the present study, we aimed to evaluate the impact of neurodegeneration of the nigrostriatal tract in a rodent model of Parkinson’s disease on the different MR contrasts (T2, T1, CBF and CBV) measured in the striatum.Material and methodsAnimals were injected with 6-hydroxydopamine (6OHDA) in the substantia nigra resulting in massive loss of nigrostriatal neurons and hence dopamine depletion in the ipsilateral striatum. Using 7T MRI imaging, we have quantified T2, T1, CBF and CBV in the striata of 6OHDA and control rats. To validate the lesion size, behavioral testing, dopamine transporter μSPECT and tyrosine hydroxylase staining were performed.ResultsNo significant differences were demonstrated in the absolute MRI values between 6OHDA animals and controls; however, 6OHDA animals showed significant striatal asymmetry for all MRI parameters in contrast to controls.ConclusionsThese PD-related asymmetry ratios might be the result of counteracting changes in both intact and affected striatum and allowed us to diagnose PD lesions. As lateralization is known to occur also in PD patients and might be expected in transgenic PD models as well, we propose that MR-derived asymmetry ratios in the striatum might be a useful tool for in vivo phenotyping of animal models of PD.

[1]  Johan Nuyts,et al.  Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  Zeger Debyser,et al.  Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. , 2007, Neurobiology of aging.

[3]  John W. Thomas,et al.  A 6-Hydroxydopamine-Induced Selective Parkinsonian Rat Model: Further Biochemical and Behavioral Characterization , 1994, Experimental Neurology.

[4]  O. Lindvall,et al.  Cerebral circulatory response to hypercapnia: Effects of lesions of central dopaminergic and serotoninergic neuron systems , 1981, Brain Research.

[5]  Christian Kolbitsch,et al.  Evaluation of Striatal Dopamine Transporter Function in Rats by in Vivo β-[123I]CIT Pinhole SPECT , 2002, NeuroImage.

[6]  J. P. Huston,et al.  UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF MESO-STRIATAL DOPAMINE NEURONS AND THEIR PHYSIOLOGICAL SEQUELAE , 1996, Progress in Neurobiology.

[7]  Patrick Dupont,et al.  Comparison between MAP and postprocessed ML for image reconstruction in emission tomography when anatomical knowledge is available , 2005, IEEE Transactions on Medical Imaging.

[8]  U. Ungerstedt.  Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. , 1971, Acta physiologica Scandinavica. Supplementum.

[9]  Khader M. Hasan,et al.  Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson’s disease , 2007, Neurobiology of Disease.

[10]  F. Ye,et al.  Basal ganglia iron content in Parkinson's disease measured with magnetic resonance , 1996, Movement disorders : official journal of the Movement Disorder Society.

[11]  Zeger Debyser,et al.  Characterization of lentiviral vector-mediated gene transfer in adult mouse brain. , 2002, Human gene therapy.

[12]  Cristina Lavini,et al.  Imaging of striatal dopamine transporters in rat brain with single pinhole SPECT and co-aligned MRI is highly reproducible. , 2003, Nuclear medicine and biology.

[13]  A. Fischman,et al.  SPECT imaging of dopamine transporter sites in normal and MPTP-Treated rhesus monkeys. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  H. Bergman,et al.  Reduced basal activity and increased functional homogeneity in sensorimotor and striatum of a Parkinson's disease rat model: a functional MRI study , 2005, The European journal of neuroscience.

[15]  J. Ridet,et al.  alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. Paxinos.  The Rat nervous system , 1985 .

[17]  H. Stanley,et al.  Common scale-invariant patterns of sleep-wake transitions across mammalian species. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Barker,et al.  Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations , 2000, Journal of neurology, neurosurgery, and psychiatry.

[20]  Koen Van Laere,et al.  Metabolic–dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson’s disease , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  Simon R. Cherry,et al.  Deficits in Striatal Dopamine D2 Receptors and Energy Metabolism Detected by in Vivo MicroPET Imaging in a Rat Model of Huntington's Disease , 2000, Experimental Neurology.

[22]  H. Bergman,et al.  Bilateral overactivation of the sensorimotor cortex in the unilateral rodent model of Parkinson's disease – a functional magnetic resonance imaging study , 2002, The European journal of neuroscience.

[23]  Paul Suetens,et al.  Optimization of geometrical calibration in pinhole SPECT , 2005, IEEE Transactions on Medical Imaging.

[24]  John Votaw,et al.  Interaction of Isoflurane with the Dopamine Transporter , 2003, Anesthesiology.

[25]  M. Defrise,et al.  Correction for imperfect camera motion and resolution recovery in pinhole SPECT , 2004, IEEE Symposium Conference Record Nuclear Science 2004..

[26]  E. Bézard,et al.  Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of parkinson’s disease , 2003, Molecular Neurobiology.

[27]  J. Booij,et al.  [123I]FP‐CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP‐lesioned monkeys , 1997, Synapse.

[28]  K. S. Bankiewicz,et al.  A 6-hydroxydopamine-induced selective parkinsonian rat model , 1989, Brain Research.

[29]  Tina K. Givrad,et al.  Changes in brain functional activation during resting and locomotor states after unilateral nigrostriatal damage in rats , 2007, NeuroImage.

[30]  R. Brooks,et al.  T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. , 1999, Radiology.

[31]  Jacques Seylaz,et al.  Cerebrovascular and metabolic uncoupling in the caudate-putamen following unilateral lesion of the mesencephalic dopaminergic neurons in the rat , 1993, Neuroscience Letters.

[32]  Yue Huang,et al.  Genetic contributions to Parkinson's disease , 2004, Brain Research Reviews.

[33]  Ji-Kyung Choi,et al.  Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling , 2006, NeuroImage.

[34]  J. P. Huston,et al.  The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments , 1996, Progress in Neurobiology.

[35]  Hagai Bergman,et al.  Manganese‐enhanced MRI in a rat model of Parkinson's disease , 2007, Journal of magnetic resonance imaging : JMRI.

[36]  B. Strooper,et al.  Neuropathology and Neurodegeneration in Rodent Brain Induced by Lentiviral Vectormediated Overexpression of α‐Synuclein , 2003, Brain pathology.

[37]  M. I. Argyropoulou,et al.  MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease , 2005, Journal of Neurology.

[38]  Erwan Bezard,et al.  Presymptomatic compensation in Parkinson's disease is not dopamine-mediated , 2003, Trends in Neurosciences.

[39]  O. Lindvall,et al.  Effects of metamphetamine on blood flow in the caudate-putamen after lesions of the nigrostriatal dopaminergic bundle in the rat , 1981, Brain Research.

[40]  Patrick Dupont,et al.  Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET , 2004, NeuroImage.

[41]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Mendez,et al.  Use of 6-hydroxydopamine to create lesions in catecholamine neurons in rats. , 1975, Journal of neurosurgery.

[43]  John R. Votaw,et al.  Isoflurane Alters the Amount of Dopamine Transporter Expressed on the Plasma Membrane in Humans , 2004, Anesthesiology.

[44]  T. Iwatsubo,et al.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Schallert,et al.  MRI, brain iron and experimental Parkinson's disease , 1992, Journal of the Neurological Sciences.

[46]  T. Jung,et al.  Regional CBF changes in Parkinson’s disease: a correlation with motor dysfunction , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[47]  H. Nishino,et al.  6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging , 2005, Experimental Neurology.